{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-22-005089","form_type":"8-K","ticker":"ITGR","cik":"0001114483","company_name":"Integer Holdings Corp","filed_at":"2022-07-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.016602+00:00","generated_at":"2026-06-24T07:17:14.076474+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Integer Q2 sales up 12% to $350M; GAAP net income falls 29%; raises FY2022 outlook","bullets":["Q2 sales $350M (+12% YoY); GAAP net income $21M (-29%); Non-GAAP adj. net income $35M (-3%).","GAAP diluted EPS $0.62; Non-GAAP adj. diluted EPS $1.04, both down YoY.","Raises FY2022 sales outlook to $1.37-1.395B (12-14% growth); organic growth 6-8%.","Cardio & Vascular sales +25%; Electrochem -1% on supplier shortages.","Total debt $947M (+$119M) from Aran acquisition; leverage ratio 3.9x adjusted EBITDA."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-22-005089","json":"https://secwatch.observer/filing/0001171843-22-005089.json","markdown":"https://secwatch.observer/filing/0001171843-22-005089.md","text":"https://secwatch.observer/filing/0001171843-22-005089.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1114483/000117184322005089/0001171843-22-005089-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1114483/000117184322005089/f8k_072822.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T07:17:14.076474+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}